BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Choi MH, Park GE, Oh SN, Park MY, Rha SE, Lee YJ, Jung SE, Choi JI. Reproducibility of mRECIST in Measurement and Response Assessment for Hepatocellular Carcinoma Treated by Transarterial Chemoembolization. Acad Radiol 2018;25:1363-73. [PMID: 29555570 DOI: 10.1016/j.acra.2018.02.013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Huicochea Castellanos S, Pagano A, Plodkowski AJ, Girshman J, Hellmann MD, Rizvi H, Flynn J, Zheng J, Capanu M, Halpenny DF, Ginsberg MS. Intra- and inter-reader agreement of iRECIST and RECIST 1.1 criteria for the assessment of tumor response in patients receiving checkpoint inhibitor immunotherapy for lung cancer. Lung Cancer 2021;161:60-7. [PMID: 34536733 DOI: 10.1016/j.lungcan.2021.08.020] [Reference Citation Analysis]
2 Cucchetti A, Casadei Gardini A. Incorporating alpha-fetoprotein within dimensional criteria for hepatocellular carcinoma transplantation. Hepatobiliary Surg Nutr 2019;8:65-6. [PMID: 30881969 DOI: 10.21037/hbsn.2018.11.02] [Reference Citation Analysis]
3 Pirasteh A, Sorra EA, Marquez H, Sibley RC, Fielding JR, Vij A, Rich NE, Arroyo A, Yopp AC, Khatri G, Singal AG, Yokoo T. LI-RADS treatment response algorithm after first-line DEB-TACE: reproducibility and prognostic value at initial post-treatment CT/MRI. Abdom Radiol (NY) 2021;46:3708-16. [PMID: 33755735 DOI: 10.1007/s00261-021-03043-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Wasnik AP. Tumor Response Criteria-Radiological Implications. Acad Radiol 2018;25:1361-2. [PMID: 30122626 DOI: 10.1016/j.acra.2018.07.011] [Reference Citation Analysis]
5 Kesler M, Levine C, Hershkovitz D, Mishani E, Menachem Y, Lerman H, Zohar Y, Shibolet O, Even-Sapir E. 68Ga-PSMA is a novel PET-CT tracer for imaging of hepatocellular carcinoma: A prospective pilot study. J Nucl Med. 2019;60:185-191. [PMID: 30002112 DOI: 10.2967/jnumed.118.214833] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 8.8] [Reference Citation Analysis]
6 Vicentin I, Mosconi C, Garanzini E, Sposito C, Serenari M, Buscemi V, Verna M, Spreafico C, Golfieri R, Mazzaferro V, De Carlis L, Cescon M, Ercolani G, Vanzulli A, Cucchetti A. Inter-center agreement of mRECIST in transplanted patients for hepatocellular carcinoma. Eur Radiol 2021. [PMID: 34117911 DOI: 10.1007/s00330-021-08088-1] [Reference Citation Analysis]
7 Krishan S, Dhiman RK, Kalra N, Sharma R, Baijal SS, Arora A, Gulati A, Eapan A, Verma A, Keshava S, Mukund A, Deva S, Chaudhary R, Ganesan K, Taneja S, Gorsi U, Gamanagatti S, Madhusudan KS, Puri P, Shalimar, Govil S, Wadhavan M, Saigal S, Kumar A, Thapar S, Duseja A, Saraf N, Khandelwal A, Mukhopadyay S, Gulati A, Shetty N, Verma N. Joint Consensus Statement of the Indian National Association for Study of the Liver and Indian Radiological and Imaging Association for the Diagnosis and Imaging of Hepatocellular Carcinoma Incorporating Liver Imaging Reporting and Data System. J Clin Exp Hepatol 2019;9:625-51. [PMID: 31695253 DOI: 10.1016/j.jceh.2019.07.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]